Vir Biotechnology Inc. and GlaxoSmithKline plc said Monday that they have commenced dosing of patients with VIR-7831 in the Phase 2/3 clinical study for their experimental COVID-19 antibody treatment.
The study will enroll about 1,300 patients worldwide who have early symptomatic infection. It will assess whether VIR-7831, as a single-dose monoclonal antibody, could prevent hospitalization due to the COVID-19.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.